TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, Jcm Ho, Emma Martin, Leslie Servidio, Martin Sandelin, Sanjay Popat
Topics & Concepts
MedicineT790MOsimertinibInternal medicineOncologyClinical endpointLung cancerCohortEpidermal growth factor receptornon-small cell lung cancer (NSCLC)SurgeryGefitinibErlotinibCancerClinical trialA549 cellLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies